QuantHealth, a Tel Aviv-based AI company, has raised $45 million in Series B funding led by Qumra Capital. Its platform simulates clinical trials by predicting how any patient will respond to any therapy, allowing pharma partners to run thousands of virtual trial variations in minutes. The capital will advance R&D, grow the team, and expand the product portfolio.
AI Simulation Funding Follows Competitor Raises
The timing comes amid a wave of investment in AI clinical development tools. Unlearn.AI raised a $50 million Series C in February 2024, while PhaseV secured a $50 million Series A in May 2025. QuantHealth's full-trial simulation approach across all arms addresses gaps left by competitors focused on narrower areas like synthetic control arms or in-trial optimization.
High Failure Rates Drive Simulation Demand
Ninety percent of drugs in clinical development fail, costing the industry roughly $45 billion per year. Current solutions rely on real-world iteration that runs trials, waits for results, and adjusts at significant cost and risk. QuantHealth's platform uses a dataset spanning 350 million patient lives and 180,000 curated clinical trials to forecast outcomes before enrollment begins.
Full-Trial Simulation Differentiates Platform
QuantHealth built an end-to-end simulation engine that outputs results in the same format as real trials, including Kaplan-Meier curves and progression-free survival analyses. This differs from Unlearn.AI's focus on digital twins for control arms or PhaseV's emphasis on optimizing ongoing trials. The company reports up to 90 percent predictive accuracy across more than 600 simulated trials in 30 indications.
"Our models simulate patient-level biology to predict responses, and identify what will actually drive a trial's success before it begins," said CEO Orr Inbar.
Strategic Investors Signal Pharma Validation
Qumra Capital led the round with participation from Pitango HealthTech, Sanofi Ventures, Artofin VC Fund, Bertelsmann Healthcare Investments, and others. The return of Sanofi Ventures, which invested earlier in 2025, and prior backing from Accenture Ventures provide direct channels into both pharma R&D organizations and consulting networks.
Market Expands as Accuracy Threshold Crosses
The AI in clinical trials market is projected to grow from between $2.7 billion and $5.5 billion in 2026 to between $25.5 billion and $77.3 billion by 2034-2035, at a CAGR of 22 to 27 percent. The in silico clinical trials segment alone is expected to reach $12.75 billion by 2034. Competitors such as Owkin, with $321 million total funding, and Insilico Medicine, which raised $110 million in a Series E in March 2025, illustrate the broader capital inflow into AI-enabled drug development.
Executive Hires Strengthen Enterprise Push
QuantHealth added six executives in six months, including Chief Medical Officer Francisco Beca from Merck and Seagen, SVP of Corporate Development Sukant Mittal from Novartis and Galderma, and VP of Scientific Strategy Flavio Dormont from Sanofi. The hires support scaling after 8x financial growth in 2025 and work with eight of the top 20 pharmaceutical companies.
Platform Expands Beyond Trial Design
With the new funding, QuantHealth plans to extend coverage to more than 40 indications in oncology and cardiometabolic disease, advance next-generation AI models, and broaden its product into competitive positioning and commercial planning. The company recently launched predictive competitive positioning capabilities and responded to an FDA docket on AI-enabled trial optimization.